Meeting Banner
Abstract #1463

CONSENSUS STATEMENT ON THE USE OF GADOLINIUM FOR MAGNETIC RESONANCE IMAGING USED IN THE DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH MULTIPLE SCLEROSIS

Jillian Katrina Chan1, Anthony Traboulsee2, Emanuel Kanal3, Kenneth Maravilla4, Lori Saslow5, Laura Barlow2, Bruce Cohen6, Kathleen Costello7, June Halper8, Colleen Harris9, David Jones10, Flavia Nelson11, Scott Newsome12, Jiwon Oh13, Daniel Pelletier14, Kottil Rammonhan15, Daniel Reich16, Alex Rovira17, Lael Stone18, Kevin Terashima16, Jerry Wolinsky11, and David Li2

1Neurology, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3University of Pittsburgh Medical Center, Pittsburgh, PA, United States, 4University of Washington, Seattle, WA, United States, 5LS Science and Medical Communications, LLC, Great Neck, NY, United States, 6Northwestern University Medical SChool, Chicago, IL, United States, 7Nathional MS Society, Maryland, MD, United States, 8Consortium of MS Centers, Hackensack, NJ, United States, 9University of Calgary, Calgary, AB, Canada, 10University of Virginia, Charlottesville, VA, United States, 11UT Health McGovern Medical School, Houston, TX, United States, 12Johns Hopkins Hospital, Baltimore, MD, United States, 13University of Toronto, Toronto, ON, Canada, 14Keck School of Medicine of USC, Los Angeles, CA, United States, 15University of Miami Multiple Sclerosis Center, Miami, FL, United States, 16Translational Neuroradiology Unit, NINDS, Bethesda, MD, United States, 17Section of Neuroradiology, Hospital Vall d'Hebron, Barcelona, Spain, 18Mellen Center for MS Treatment and Research, Cleveland, OH, United States

Clinical guidelines for the diagnosis and follow-up of multiple sclerosis recommends brain MR imaging with gadolinium based contrast agents. Our aim was to address concerns about the use of gadolinium, the risk of accumulation in the brain and propose changes to clinical guidelines published in 2016. Group consensus is that GBCA remain essential in the diagnostic evaluation of a patient suspected of having MS to demonstrate active inflammatory lesions. GBCA should be used judiciously, minimizing gadolinium exposure and dose when possible.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract